论文部分内容阅读
作者从8例癌性胸水中用不连续密度梯度离心法分离淋巴细胞和肿瘤细胞,在rIL-2存在下维持细胞浓度为5×10~5个/ml进行培养扩增,并在培养的不同时期测定细胞毒活性及细胞表型.结果表明:癌性胸水LAK细胞在培养期间具有良好的扩增速度,在培养20d后扩增至原来的60～210倍,培养10～15d时8例癌性胸水LAK细胞对K_(562)和LiBr血细胞(效靶比为25:1)的平均杀伤活性分别为61.6％和66.3％,对新鲜自体肿瘤细胞(3例)的杀伤活性平均为46.6％,经统计学检验相差不显著(P>0.05).癌性胸水LAK细胞在培养7～21d间对K_(562)和LiBr的杀伤活性维持于较高水平,而自21d后开始下降.在培养21d期间,CD3~+细胞百分率无明显变化,CD4~+细胞有所增高,而CD8~+细胞有所下降.
The authors isolated lymphocytes and tumor cells from 8 cases of cancerous pleural effusion by discontinuous density gradient centrifugation and maintained the cell concentration in the presence of rIL-2 at a concentration of 5 x 10~5 cells/ml for culture and expansion. The cytotoxic activity and cell phenotype were measured at the time. The results showed that the cancerous pleural effusion LAK cells had a good amplification rate during the culture, and it expanded to 60-210 times after 20 days culture, and 8 cases when cultured for 10-15 days. The average killing activity of pleural LAK cells against K_(562) and LiBr blood cells (Effi-to-target ratio of 25:1) was 61.6% and 66.3%, respectively. The average killing activity against fresh autologous tumor cells (3 cases) was 46.6%. There was no statistically significant difference (P>0.05). The killing activity of cancerous pleural effusion LAK cells on K562 and LiBr maintained at a high level for 7 to 21 days, and decreased from 21 days onwards. During the period, there was no significant change in the percentage of CD3~+ cells, CD4~+ cells increased, and CD8~+ cells decreased.